Clinical trial Recruiting at 1 site Interventional Ages 7 to 18

Using virtual reality to reduce stress in children undergoing proton therapy

Official title: Virtual Reality for Children in Radiotherapy (REVER)

Run by Centre Antoine Lacassagne · NCT04934293 · Data updated 2026-11-12

This study is testing whether using virtual reality can help reduce stress and anxiety in children receiving proton therapy for cancer treatment.

Quick facts

Study typeInterventional
Ages7 Years to 18 Years
SexAll
Enrollment47 (estimated)
SponsorCentre Antoine Lacassagne
Academic / other
Drugs / interventionschemotherapy, radiation
Locations1 site (Nice)
StatusRecruiting
StartedAugust 2, 2021
Main results expectedFebruary 2027
Study endsFebruary 2027
Registry record updatedMay 29, 2026
Trial IDNCT04934293 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children aged 7 to 18 years receiving proton therapy at the Antoine LACASSAGNE Center.

Probably not a fit

Patients under 7 or over 18 years old, those under general anesthesia, or with certain medical conditions may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness of virtual reality in reducing anxiety for pediatric patients receiving proton therapy for cancer treatment. By creating a more relaxed environment, the study seeks to minimize the discomfort associated with the long and uncomfortable positioning required during irradiation. The effectiveness will be evaluated through both objective measures, such as placement time and helmet tolerance, and subjective measures, including perceived anxiety through questionnaires. This is the first pediatric-focused study utilizing virtual reality in this context, supported by the French Group of Pediatric Radiotherapists.

Why it matters

Potential benefit: If successful, this approach could significantly reduce anxiety and improve the overall experience of children undergoing proton therapy.

How similar studies have gone: While this is the first pediatric virtual reality study in this context, similar approaches in other settings have shown promise in reducing anxiety.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patient treated at the Antoine LACASSAGNE Center for treatment by proton therapy
* Age ≥ 7 years old and ≤ 18 years old
* Patient, and parents for minor children, having read the information notice and signed the informed consent,
* Patient with social security coverage.

Exclusion Criteria:

* Age \< 7 years old and \> 18 years old,
* Patient under general anesthesia,
* Patient suffering from wounds or infections in the head, deemed incompatible with the use of the helmet by the investigator,
* Patient suffering from respiratory problems,
* Patient suffering from a high level of claustrophobia,
* Patient followed for a psychiatric pathology,
* Patient suffering from unbalanced epilepsy,
* Patient suffering from visual (binocular vision) and / or hearing disorders preventing the use of virtual reality,
* Patient whose head circumference is insufficient for the use of the helmet, deemed incompatible with the use of the helmet by the investigator,
* Patient treated by radio chemotherapy.

Where it's running

  • Centre Antoine Lacassagne
    Nice, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.